Is Cytokinetics, Incorporated (NASDAQ:CYTK) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Cytokinetics, Incorporated at current levels.
Aficamten is now MYQORZO, the launch is live, and Cytokinetics is one heart failure label expansion away from a takeout.
Where CYTK is headed
Cytokinetics finally crossed the line. MYQORZO (aficamten) is on the market for obstructive hypertrophic cardiomyopathy, the +1125% revenue line above is the first taste of a real commercial drug rather than collaboration milestones, and the company is no longer a binary clinical-stage story. The interesting question now is not whether the drug works, it does, but how big the obHCM opportunity actually is once cardiologists have a second mechanism to reach for alongside Bristol's Camzyos, and how fast Cytokinetics can stretch the molecule into non-obstructive HCM and adjacent indications.
Read the full Compass Direction on CYTK
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $70.15).
See the full CYTK analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Cytokinetics, Incorporated (NASDAQ:CYTK) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Cytokinetics, Incorporated at current levels. Aficamten is now MYQORZO, the launch is live, and Cytokinetics is one heart failure label expansion away from a takeout.
What is CYTK's Compass Score?
Cytokinetics, Incorporated scores 77/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for CYTK?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the CYTK page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.